Erratum to “Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018))

Martin Bögemann^*
, Neal D Shore
, Matthew R Smith
, Teuvo L J Tammela
, Albertas Ulys
, Egils Vjaters
, Sergey Polyakov
, Mindaugas Jievaltas
, Murilo Luz
, Boris Alekseev
, Thierry Lebret
, Martin Schostak
, Frank Verholen
, Marie-Aude Le Berre
, Shankar Srinivasan
, Jorge Ortiz
, Ateesha F Mohamed
, Toni Sarapohja
, Karim Fizazi

^*Corresponding author for this work

Research output: Contribution to journal › Erratum

1 Citation (Scopus)

1 Citations
1 Article

1 results
- Publication Year, Title(ascending)
- Title

Filter

2023
Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial
Bögemann, M., Shore, N. D., Smith, M. R., Tammela, T. L. J., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, B., Lebret, T., Schostak, M., Verholen, F., Le Berre, M. A., Srinivasan, S., Ortiz, J., Mohamed, A. F., Sarapohja, T. & Fizazi, K., Mar 2023, In: European Urology. 83, 3, p. 212-221 10 p.
Research output: Contribution to journal › Article › peer-review

Open Access
11 Citations (Scopus)